EBV Replication and transcription activator 198-206, TYPVLEEMF
Description
About EBV Replication and transcription activator 198-206, TYPVLEEMF
The Epstein-Barr Virus (EBV) (strain AG876) Replication and transcription activator (BRLF1) Peptide (IEDB: 67419) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Replication and transcription activator (BRLF1) Peptide, H-TYPVLEEMF-OH (Uniprot: Q1HVG0 aa: 198-206) from JPT is produced under strict quality control and quality management.
EBV Replication and transcription activator 198-206, TYPVLEEMF - Specifications
- Peptide sequence: H-TYPVLEEMF-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Infection
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for EBV Replication and transcription activator 198-206, TYPVLEEMF
References:
Read References with JPT’s Antigen Peptides
EBV Replication and transcription activator 198-206, TYPVLEEMF has been described in:
Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific CD8+ T cells., Blood, 2003 (PMID: 12393434)
T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells., Cytotherapy, 2015 (PMID: 26276009)
High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome., Mol Cell Proteomics, 2018 (PMID: 29242379)
Documentation
Documentation for EBV Replication and transcription activator 198-206, TYPVLEEMF
Properties
Properties of EBV Replication and transcription activator 198-206, TYPVLEEMF
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Infection |
Layout: | Freeze-dried in glass vial |
Organism: | Epstein-Barr Virus (EBV) |
Protein Name: | Replication and transcription activator (BRLF1) |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to EBV Replication and transcription activator 198-206, TYPVLEEMF
Information | Values |
---|---|
Sequence: | H-TYPVLEEMF-OH |
Specifications: | 9mer peptide as TFA salt |